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Abstract
Gradual rewarming from hypothermic to normothermic is a novel perfusion mo-
dality with superior outcome to sudden rewarming to normothermic. However, the 
identification of an oxygen carrier that could function at a temperature range from 
4 to 7°C or whether it is necessary to use oxygen carrier during kidney rewarming, 
remains unresolved. This study was designed to test the use of a hemoglobin‐based 
oxygen carrier (HBOC) during gradual kidney rewarming as an alternative to simple 
dissolved oxygen. In this study, 10 rat kidneys were randomly divided into the con-
trol and the HBOC group. In the control group, no oxygen carrier was used during 
rewarming perfusion and the perfusion solution was oxygenated only by apply-
ing diffused carbogen flow. The protocol mimicked a donor after circulatory death 
(DCD) kidney transplantation, where after 30 minutes warm ischemia and 120 min-
utes cold storage in University of Wisconsin solution, the DCD kidneys underwent 
gradual rewarming from 10 to 37°C during 90 minutes with or without HBOC. This 
was followed by 30 minutes of warm ischemia in room temperature to mimic the 
anastomosis time and 120 minutes of reperfusion at 37°C to mimic the early post‐
transplant state of the graft. The HBOC group demonstrated superior kidney function 
which was highlighted by higher ultrafiltrate production, better glomerular filtration 
rate and improved sodium reabsorption. There was no significant difference between 
the 2 groups regarding the hemodynamics, tissue injury, and adenosine triphosphate 
levels. In conclusion, this study suggests better renal function recovery in DCD kid-
neys after rewarming with HBOC compared to rewarming without an oxygen carrier.
K E Y W O R D S
donor after circulatory death kidney graft, hemoglobin‐based oxygen carrier, oxygen carrier, perfusion, 
rewarming perfusion
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1 |  INTRODUCTION
One of the challenges in organ transplant is improving the organ 
preservation method especially in the grafts with inferior quality 
such as donor after circulatory death (DCD).1,2 Machine perfu-
sion has been developed as an alternative preservation method 
to cold storage (CS) with promising results in organ quality 
improvement.3‒5 Different perfusion protocols have been 
studied by many groups and among the emerged perfusion 
protocols, normothermic machine perfusion has gained more 
attention as it provides the feasibility of assessing organ viabil-
ity and function before transplant.6,7 It has also been shown that 
gradual rewarming from hypothermic to normothermic is su-
perior to sudden normothermic perfusion after CS.4,8 Although 
gradual rewarming solves the problem strategically, it remains 
to be established whether there is a need for oxygen carrier 
during gradual rewarming for providing a sufficient amount of 
oxygen. Red blood cells (RBCs) have been mainly used in nor-
mothermic perfusion, however there is major biophysical limits 
such as hemolysis and rheological complications when submit-
ted to temperatures below normothermic (37°C).9 Artificial 
oxygen carriers, either with hemoglobin‐based or perfluoro-
carbon‐based, are the relatively new solutions to this problem. 
After disappointing results with perfluorocarbons10,11, HBOCs 
with the ability of functioning in wide range of temperature, 
from hypothermic to normothermic, seem to be an option for 
gradual rewarming and a potential alternative to blood in nor-
mothermic perfusion.12 HBOC‐201  (Hemopure) is a second 
generation glutaraldehyde‐polymerized hemoglobin of bovine 
origin that can function as an oxygen bridge in order to pre-
serve oxygen carrying capacity in the lack of RBCs.12 HBOCs 
have been used in subnormothermic and normothermic perfu-
sion and the data suggested improved organ quality.12‒14 In this 
study, our aim was to investigate the viability and efficacy of 
HBOC‐based perfusion solution in gradual rewarming perfu-
sion in a rat kidney model.
2 |  MATERIALS AND METHODS
2.1 | Experimental animals and kidney 
procurement
Male Lewis rats weighing 290‐350 g were used in this study. 
Animals received care according to the National Research 
Council guidelines on animal experiments. The study proto-
col was approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Massachusetts General Hospital. 
Anesthesia and surgical details of recovery are provided 
elsewhere.15 Briefly, the rats were anesthetized using 5% 
of isoflurane and heparin administration was performed by 
injection of 1 mL of 0.9% of NaCl with 500 IU of heparin 
via the dorsal penile vein. Next, the ureter was cannulated 
with regard to monitor ultrafiltrate production during gradual 
rewarming and reperfusion. For controlled warm ischemia, 
during cessation of circulation the animal was kept at 37°C 
for 30 minutes, then renal artery was cannulated using a 20‐G 
intravenous catheter and the kidney was flushed through the 
renal artery with 10 mL of 0.9% of NaCl at room temperature 
followed by 10 mL University of Wisconsin (UW) preserva-
tion solution at 4°C. Afterwards, the kidneys were removed 
and stored in cold UW (4°C) during CS preservation for 120 
minutes.
2.2 | Experimental design and 
perfusion solutions
2.2.1 | Rewarming and reperfusion
A total number of 10 rat kidneys were divided into 2 experimen-
tal groups (group 1‐Control, group 2‐HBOC). In both groups, 
after DCD procurement (n = 5 per group), grafts were pre-
served for 120 minutes during CS in UW media. Then, grafts 
underwent gradual rewarming perfusion from 10 to 37°C for 
90 minutes. Temperature of the perfusion solution was set at 
10°C at the beginning of rewarming in both groups, which 
is the minimum allowed by the equipment. Temperature was 
stable at 10°C for the first 15 minutes of the rewarming phase, 
and was then gradually increased to 37°C over 60 minutes 
by gradually increasing the temperature of thermostat and ar-
terial flow. The temperature was kept stable at 37°C for the 
final 30 minutes of rewarming perfusion. Pressure was also 
observed during the rewarming phase, with the range of 20‐40 
mm Hg in the hypothermic phase, 40‐80 mm Hg in transac-
tion from hypothermia to normothermia and 80‐100 mm Hg 
in the normothermic phase of the rewarming protocol.
Afterwards, the grafts were flushed with 10 mL of cold 
saline and stored in a petri dish covered with wet gauze at 
room temperature for 30 minutes, in order to mimic surgi-
cal implantation period. Subsequently, the kidney grafts were 
reperfused at 37°C for 120 minutes. The flow was set at 
8 mL/min in the beginning of reperfusion, and afterwards 
was gradually increased with keeping the pressure in physio-
logical range (80‐110 mm Hg) (Figure 1).
2.3 | Gradual rewarming perfusion media
2.3.1 | HBOC group
The perfusion solution consisted of Williams Medium E 
(Sigma‐Aldrich, St Louis, MO, USA) supplemented with 
heparin (1000 U/L APP Pharmaceuticals, Schaumberg, 
IL, USA), albumin 15% (Sigma‐Aldrich), creatinine 
(1000 µmol/L) and 25% HBOC‐201 v/v (provided by 
Hemoglobin Oxygen Therapeutics, Souderton, PA, USA). 
The solution was oxygenated with a carbogen mixture of 
95% of O2 and 5% of CO2 in the arterial flow and saturation 
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SaO2 > 97% (Table 1). In all the experiments before connect-
ing the kidney, the perfusion solutions were checked to be in 
physiological osmolarity, oncotic pressure range, and contain 
adequate oxygen amount (>400 mm Hg).
2.3.2 | Control group
The same media was used in the control group, except no   
HBOC was used during rewarming perfusion and the HBOC 
volume was replaced with Williams Medium E solution. The 
composition of both perfusion media is available in (Table 1).
For reperfusion assessment of the simulated transplant, 
the perfusion formula with HBOC was used in both groups.
The perfusion device was flushed, cleaned, and the system 
was primed with fresh HBOC media for reperfusion during 
the 30 min simulated anastomosis time.
2.3.3 | HBOC
This acellular hemoglobin was produced by purifying bovine 
hemoglobin and was polymerized to decrease the potential 
side effects and alleviate the risk of toxicities. HBOC with a 
molecular weight of 250 kDa and in vivo half‐life time of 20 
hours, can be stored at 2‐30°C for up to 3 years.12,13 The oxy-
gen affinity of HBOC is regulated by chloride ion concen-
tration which means that oxygen‐HBOC dissociation curve 
shifts to right and HBOC releases oxygen to tissue more 
freely compared to other carriers like human hemoglobin 
with HBOC P50 around 40 mm Hg (±6 mm Hg) at 37°C com-
pared to 27 mm Hg of  human hemoglobin.13 In general, the 
effects of temperature on oxygen affinity of HBOC are simi-
lar to the effects of temperature on native (corpuscular) Hb, 
which means that oxygen affinity increases by temperature 
decrease (low in hypothermic and higher in normothermic 
temperature). However, across all temperatures HBOC dem-
onstrates high tendency to release oxygen which is still better 
than Hb in erythrocytes.16
2.3.4 | Perfusion system
The perfusion device is a flow‐controlled system for rodent 
organ perfusion. The device consists of a Roller pump (Cole 
Parmer, Cat. No. HV‐07522‐20), Oxygenator containing 
silicon tubing and providing Carbogen and heat exchanger 
(Radnoti, Cat. No. 130144), Bubble trap (Radnoti, Cat. No. 
130149), Pressure probe (Living Systems, Cat. No. PM‐P‐1), 
Circulating controlled rate chiller (Neslab, Cat. No. RTE‐111) 
and Organ chamber (Radnoti, Cat. no 158360) (Figure 2, Part I). 
(Figure 2, Part II) shows a cannulated kidney graft in the 
organ chamber during perfusion.
F I G U R E  1  Experimental design. Illustrates the experimental design of the study and the duration in each section of the experiments [Color 
figure can be viewed at wileyonlinelibrary.com]
Experimental Design'&'PLQ& &6PLQ& 5HZDUPLQJPLQ1R+%2&& $QDVWRPRVLVPLQ& 5HSHUIXVLRQPLQ:LWK+%2&&'&'PLQ& &6PLQ& 5HZDUPLQJPLQ:LWK+%2&& $QDVWRPRVLVPLQ& 5HSHUIXVLRQPLQ:LWK+%2&&
T A B L E  1  Rewarming media
Control HBOC P value
pH 7.5 ± 0.07 7.42 ± 0.14 .886
PCO2 (mm Hg) 36.2 ± 31.4 32.2 ± 12.5 .629
PO2 (mm Hg) 590 ± 96.0 452 ± 5.0 .200
BE (mmol/L) 2 ± 5.0 −3 ± 5.0 .057
HCO3− (mmol/L) 26.2 ± 4.1 25.8 ± 2.6 .000
Na+ (mmol/L) 147 ± 0.75 149 ± 2.0 .016
K+ (mmol/L) 5.0 ± 0.2 5 ± 0.1 .730
Cl− (mmol/L) 115 ± 2.5 115 ± 3 .690
HGB (g/dL) – 3.0 –
SO2 (%) – 100% –
Lactate (mmol/L) 0.03 ± 0.0 2.6 ± 0.1 .016
Note: Represents and compares the biochemical composition of the perfusion 
solution in the control and HBOC groups, used in rewarming phase.
4 |   MAHBOUB et Al.
2.3.5 | Perfusion profile
During rewarming and reperfusion phase in both groups, flow 
and pressure were recorded at 30 minutes intervals and sub-
sequently the resistance was calculated. pH and pO2 in the 
perfusate samples were measured every 30 minutes. Lactate 
concentration in the perfusate samples was measured and 
recorded every 30 minutes during 120 minutes of reperfu-
sion. I‐Stat analyzer (Abbott, Lake Bluff, IL, USA) was used 
to measure pO2 in the arterial and venous sides, pH and lactate 
levels, and in general to monitor hemodynamic, chemistry, and 
electrolytes profile in the perfusate and ultrafiltrate samples. 
In order to monitor potential edema formation in the organs, 
the kidney grafts were weighed before, and after both rewarm-
ing and reperfusion phases. Consequently, the weight gain per-
centage was calculated (increase/original weight × 100).
To measure methemoglobin (Met‐Hb) level in the 
perfusate samples, we used RAPIDPoint 500 (Siemens, 
Washington, D.C., USA). Met_Hb was measured in the sam-
ples before, during and after perfusion.
2.3.6 | Ultrafiltrate production and 
renal function
The produced ultrafiltrate was collected in Eppendorf 
tubes and was measured in milliliters (mL) in 30 minute 
intervals during reperfusion phase in the both HBOC and 
control groups. Glomerular filtration rate (GFR) (ultrafil-
trate creatinine × ultrafiltrate volume/perfusate creatinine) 
and fractional sodium re‐absorption ((perfusate sodium‐ 
ultrafiltrate sodium)/(perfusate sodium) ×100) were 
calculated accordingly.4
2.3.7 | Oxygen consumption
Oxygen consumption during reperfusion was calculated in 
the HBOC group during rewarming and in the both groups 
during reperfusion using the following formula:
([{ApO2−VpO2} × K /760] × total flow) + ([{AsO2−
VsO2} × Hb × c × 0.0001] × flow)/Kidney weight × 100. In 
which pO2 was in mm Hg, sO2 in %, Hb in g/dL, Renal artery 
flow in mL/min and kidney weight in g. c the oxygen binding 
capacity of HBOC (1.26) and K was a constant (0.0225).16
2.3.8 | Tissue energy state
The tissue samples to determine energy cofactors adeno-
sine monophosphate (AMP), adenosine diphosphate (ADP) 
and adenosine triphosphate (ATP) were taken at the end of 
reperfusion (t = 120 minutes) in order to prevent induc-
ing injury to the renal grafts during rewarming and rep-
erfusion. Method for the extraction and measurement has 
been described previously.17 Briefly, after extracting the 
metabolites using a mixture of methanol/chloroform and 
3 freeze‐thaw cycles, cold water (4°C) was added to the 
extracts and the extracts were centrifuged. Then, the analy-
sis was started by transferring the top phase of the mix-
ture into the sample vial. The frozen tissue samples were 
F I G U R E  2  Graphic representation of 
the rodent kidney perfusion system. Part I: 
A, Solution reservoir; B, Roller pump; C, 
Heat exchanger and oxygenator containing 
silicone tubing and providing carbogen; 
D, Bubble trap; E, Pressure probe; F, 
Organ chamber; G, Urine Eppendorf; H, 
Thermostat which regulates the temperature. 
Part II: This picture shows a cannulated rat 
kidney during machine perfusion [Color 
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analyzed using a chromatography‐mass spectrometry sys-
tem (AB Sciex, Foster City, CA, USA).
Energy charge was calculated as:
Energy charge = [2ATP + ADP]/[ATP + ADP + AMP]
2.3.9 | Renal injury & 
histological evaluation
Lactic acid dehydrogenase (LDH) was measured in the per-
fusate samples using Elisa kit (# MBS041480 MyBioSource, 
Inc., San Diego, CA, USA) during reperfusion in the both 
HBOC and control groups. Of note, we did not measure lac-
tate and LDH in the rewarming phase as HBOC interference 
with these assays and subsequently the HBOC group data 
would include false positive data. We did the measurements 
in the reperfusion as both groups had the same perfusion 
environment regarding HBOC level. Biopsies were obtained 
from the renal tissues at the end of 120 minutes reperfusion 
and stored in 10% of formalin for histological evaluation. 
Paraffin‐embedded slides of kidney biopsies were prepared 
for hematoxylin and eosin (H&E).
2.4 | Statistical analysis
Continuous data were presented as the median and interquar-
tile range (IQR). Mann‐Whitney U test was used to compare 
groups. A P value of less than .05 was considered significant. 
Analyses were performed using SPSS software version 25.0 
for Windows (SPSS Inc., Chicago, IL, USA).
3 |  RESULTS
3.1 | Rewarming
3.1.1 | Perfusion profile in rewarming phase
Temperature profile in the control and HBOC groups dur-
ing rewarming is shown in (Figure 3A). Renal resistance 
slightly decreased toward the end of rewarming perfusion 
with no significant difference between the HBOC and control 
groups (Figure 3B). Both groups showed normal pH within 
physiological range (7.34‐7.45) through the 90 minutes 
of rewarming perfusion with no significant difference 
(Figure 3C).
3.1.2 | Perfusion profile during reperfusion
The resistance in renal artery was higher at the beginning of 
reperfusion in the HBOC group. It decreased gradually and 
there was no significant difference during the rest of reperfu-
sion between the 2 groups (Figure 4A). pH was within physi-
ological range in the both HBOC and control groups with 
no significant difference (Figure 4B). No significant differ-
ence was found in the lactate concentration in both groups 
during 120 minutes of reperfusion (Figure 4C). The kidney 
grafts weigh scan revealed no significant edema level in both 
groups with a median of (10.5% vs. 12.5%) in the rewarm-
ing and (2.5% vs. 7.4%) in the reperfusion phase. The com-
parison between groups (control & HBOC) and the phases 
F I G U R E  3  Kidney profile during gradual rewarming. A, Temperature. B, Renal Resistance, which slightly reduced during gradual 
rewarming in the both HBOC and control groups. C, pH was in the physiologic range during gradual rewarming. D, Oxygen consumption  [Color 
figure can be viewed at wileyonlinelibrary.com]
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(rewarming & reperfusion) did not reveal a significant differ-
ence (Figure 4D).
We observed gradual rise in Met_Hb level during rewarm-
ing (Figure 5A) and more drastically in normothermic reper-
fusion, with no significant difference between control and 
HBOC group during reperfusion phase (Figure 5B).
3.1.3 | Functional parameters during 
reperfusion
Ultrafiltrate production gradually decreased in the control 
group during 120 minutes of reperfusion while it gradually 
increased in the HBOC group with the statistical difference 
at t = 90 (P = .05) (Figure 6A). GFR rate was higher in the 
HBOC group during the 120 minutes of reperfusion with the 
statistical difference at t = 90 (P = .32) compared to the con-
trol group (Figure 6B). Fractional sodium re‐absorption was 
improved in the HBOC group compared to the control group 
during 120 minutes of reperfusion and this reached statisti-
cal significance at t = 90 (P = .017) and t = 120 (P = .032) 
(Figure 6C). It was notable that re‐absorption completely 
ceased in the control group after 90 minutes of reperfusion, 
but was stable throughout in the HBOC group.
3.1.4 | Oxygen consumption and 
energy state
Oxygen consumption was gradually increased parallel to an 
increase in the temperature over 90 minutes rewarming phase 
in the group with HBOC (Figure 7A). Oxygen consumption 
could not be calculated in the control group during rewarming 
due to absence of an oxygen carrier, therefore the difference 
of pO2 in the arterial and venous was calculated (Figure 7B).
Oxygen consumption was also observed in the both 
groups during 120 minutes of reperfusion with no 
difference found between the control and HBOC groups 
(Figure 7C). After 120 minutes of reperfusion, the HBOC 
group trended higher in terms of ATP and energy charge, 
however, the difference did not reach statistical difference 
(Figure 7D,E).
F I G U R E  4  Kidney profile during 
reperfusion. A, Resistance was high in 
the both groups in the beginning of the 
reperfusion with significant difference, and 
then was reduced in both groups toward the 
end of reperfusion with no difference. B, 
pH was in normal range in the both groups 
with no significant difference. C, There 
was no significant difference in the lactate 
level between both groups. D, This graph 
indicates the weight gain during rewarming 
and reperfusion phase in both groups with 
no significant difference. *P ≤ 0.05 [Color 
figure can be viewed at wileyonlinelibrary.
com]
F I G U R E  5  Kidney Met‐Hb during 
rewarming and reperfusion. A, Represents 
Met‐Hb level in the HBOC group during 
rewarming. B, Indicates a gradual increase 
in Met‐Hb level in the both HBOC and 
control groups during 120 minutes of 
reperfusion [Color figure can be viewed at 
wileyonlinelibrary.com]
   | 7MAHBOUB et Al.
3.1.5 | Renal parenchymal injury & 
histological evaluation
There was no difference in LDH between the 2 groups during 
reperfusion (Figure 8, Part I). Light microscopy performed 
on tissue samples obtained at the end of the 120 minutes rep-
erfusion also did not show significant differences between 
the HBOC group and the control group. Overall only slight 
changes of normal structural appearance like epithelial shed-
ding was observed in both groups (Figure 8, Part II, A & B).
4 |  DISCUSSION
The aim of our study was to assess whether the supple-
ment of HBOC during gradual rewarming in DCD kidneys 
recovers and improves renal function, as viability testing 
was evaluated during 120 minutes of reperfusion at 37°C. 
Our study indicates that 90 minutes gradual rewarming with 
HBOC after CS could improve renal function compared to 
gradual rewarming alone. The improvements in renal func-
tion are highlighted by a higher trend of ultrafiltrate produc-
tion, better GFR and improved sodium reabsorption during 
reperfusion phase. Although the kidneys in the HBOC 
group showed higher trend of ATP content and elevated 
energy charge status, these findings did not reach a signifi-
cant difference.
It has been established that combination of warm and cold 
ischemia in DCD kidneys leads to severe ischemia reperfu-
sion injury and subsequently increases the rate of delayed 
graft function after transplant and shortens long‐term graft 
survival.18 Urine production is the first sign of graft func-
tion after transplant and the urine volume may correlate with 
graft survival post‐transplant.19 Alongside urine volume, the 
quality of urine also plays an important role, for instance, 
GFR as a marker of renal glomerular function is used as a 
predictor factor of patient survival after kidney transplant.20 
HBOC group demonstrated better graft function with higher 
trend of ultrafiltrate production and improved GFR compared 
to control group. Fractional sodium re‐absorption is another 
functional parameter as a marker of renal tubular function.21 
Tubular function is an energy demanding process and suffi-
cient oxygenation is required to provide adequate energy.21 
HBOC group also showed improved tubular function and 
recovery indicated by superior sodium reabsorption.
HBOC has originally been developed as an alternative 
to RBCs in emergency care and trauma in the acutely ane-
mic patients; however, the use in human trials has been lim-
ited due to hypertensive response as a result of nitric oxide 
(NO) depletion and vasoconstriction.22 We therefore closely 
observed the resistance during both rewarming and reperfu-
sion by monitoring pressure and flow, HBOC caused higher 
resistance in the beginning of the both rewarming and reper-
fusion phases, however, it quickly decreased with no sign of 
F I G U R E  6  Kidneys undergoing gradual rewarming show improved function and recovery compared to controls during reperfusion. A, The 
volume of ultrafiltrate production was measured every 30 minutes and was improved in the HBOC group and this was significant at t = 90.  
B, GFR was superior in the HBOC group with significant differences at t = 90. C, Fractional sodium re‐absorption was gradually increased in the 
HBOC group while it was decreased in the control group with significant differences at t = 90 and t = 120. *P ≤ 0.05 [Color figure can be viewed 
at wileyonlinelibrary.com]
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sustained hypertension. The use of HBOC in liver normo-
thermic perfusion also did not report higher pressure and 
resistance13,14 which is in line with our findings. In the con-
text of machine perfusion, these findings could be useful for 
translating to clinical studies as HBOC will be flushed out 
before graft implantation in recipient.
Fontes et al have tested HBOC in a preclinical porcine 
model during prolonged subnormothermic perfusion with 
the outcome indicating consistent oxygen delivery and ade-
quate graft function after transplant.12 The use of HBOC in 
2 discarded human liver studies reported the feasibility and 
safety of applying HBOC‐based perfusion media during 
normothermic machine perfusion (NMP) as an alternative 
to RBCs.13,14 A recent study by de Vries et al described the 
use of HBOC in a pretransplant combined dual oxygenate 
hypothermic machine perfusion (D‐HOPE) with controlled 
oxygenated rewarming (COR) to NMP in initially declined 
human liver grafts.16 The study presented promising results 
for further future use of HBOCs in clinical studies with 
the outcome of 100% patient survival in the first 3 months 
post‐transplant.
Although HBOC has been used in a number of liver per-
fusion studies with improved perfusion parameters, the liver 
studies were either preclinical or clinical with small popula-
tion and limited information about HBOC in human kidney 
perfusion. Hence, further studies could assess the effects of 
HBOC‐based perfusion solution in a comprehensive clinical 
trial model.
Due to the lack of NADH‐dependent enzyme (methemo-
globin reductase) in HBOC, the possibility of Met‐Hb pro-
duction is a disadvantage associated with HBOC use and the 
gradual rise in Met_Hb level has been previously reported.16 
Our experiments also revealed a slight increase in the Met‐Hb 
during rewarming and more extreme during reperfusion. In 
spite of higher Met‐Hb formation, the risk of Met‐Hb transfer 
after perfusion to the organ recipient's body is negligible as 
F I G U R E  7  Graphical presentation of oxygen concentration, ATP level, and energy charge ratio in the rewarming and control groups. A, This 
graph demonstrates oxygen consumption during 90 minutes rewarming in the HBOC group. B, The difference between arterial pO2 and venous 
pO2 during rewarming phase in the control groups is shown in this graph. C, Oxygen consumption remained the same in the both groups during 
reperfusion. D, E, ATP and energy charge ratio trended higher in the HBOC group with no significant difference between the groups [Color figure 
can be viewed at wileyonlinelibrary.com]
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the perfusion solutions get flushed out of the organ prior to 
transplantation.14
This study as a preclinical kidney rewarming model pres-
ents supportive information about the feasibility of HBOC use 
in renal perfusion and the effective outcome on renal function. 
However, lack of transplantation validation is a limitation of 
our study and the next phase would be to validate this data in 
a transplant model. The other limitation is that although posi-
tive effect of HBOC on kidney function could be due to better 
oxygen carrying capacity of HBOC, nevertheless, we did not 
specifically study the O2 carrying capacity in this study and 
this could be further investigated in future studies.
5 |  CONCLUSION
This study is the first report on using HBOC‐201 in the grad-
ual rewarming kidney model with improved kidney function. 
Altogether, this proposes the possibility of using HBOCs in 
the future in different perfusion setups as a potential oxygen 
carrier in different temperatures.
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